Vir Biotechnology (VIR) Current Deferred Revenue (2018 - 2025)

Vir Biotechnology has reported Current Deferred Revenue for 8 years, with the latest figure at $10.1 million in Q2 2025.

• Quarterly Current Deferred Revenue fell 39.47% year-over-year to $10.1 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $10.1 million (down 39.47% YoY) and the FY2024 annual result came in at $12.6 million, down 80.5% from the prior year.
• Current Deferred Revenue eased to $10.1 million in Q2 2025 per VIR's latest filing, from $11.9 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $262.9 million in Q1 2021 and troughed at $10.1 million in Q2 2025.
• A 5-year average of $48.0 million and a median of $16.2 million in 2023 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2021 and 2022: Current Deferred Revenue jumped 5148.08% in 2021, then sank 94.1% in 2022.
• Over 5 years, Current Deferred Revenue stood at $98.2 million in 2021, then sank by 84.2% to $15.5 million in 2022, then soared by 317.95% to $64.9 million in 2023, then sank by 80.5% to $12.6 million in 2024, then retreated by 20.07% to $10.1 million in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $10.1 million, $11.9 million, and $12.6 million for Q2 2025, Q1 2025, and Q4 2024 respectively.